- 1 When Two plus Four Does Not Equal Six: Combining
- 2 Computational and Functional Evidence Towards Classification
- 3 of BRCA1 Key Domain Missense Substitutions.
- 4
- Author List: Scott T. Pew,¹ Madison B. Wiffler,² Alun Thomas,³ Julie L. Boyle,^{4,5} Melissa S. Cline,⁶ Nicola J. Camp,^{5,7} David E. Goldgar,^{5,8} Sean V. Tavtigian^{1,5*} 5
- 6
- 7
- Affiliations: 8
- 9 1. Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, 10 Utah, 84112, USA
- 11 2. Department of Neurobiology, University of Utah School of Medicine, Salt Lake City, Utah, 12 84112. USA
- 13 3. Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, 84108, USA 14
- 4. Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt 15 Lake City, Utah, 84108, USA 16
- 17 5. Huntsman Cancer Institute, Salt Lake City, Utah, 84108, USA
- 18 6. UC Santa Cruz Genomics Institute, Genomics, University of California, Santa Cruz, CA, 95064, USA 19
- 20 7. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, 21 84108, USA
- 22 8. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, 23 84108, USA
- 24 Correspondence: sean.tavtigian@hci.utah.edu.

25

26

29 ABSTRACT

Classification of genetic variants remains an obstacle to realizing the full potential of 30 31 clinical genetic sequencing. Because of their ability to interrogate large numbers of variants, 32 multiplexed assays of variant effect (MAVEs) and computational tools are viewed as a critical 33 part of the solution to variant classification uncertainty. However, the (ioint) performance of 34 these assays and tools on novel variants has not been established. Transformation of the 35 gualitative classification guidelines developed by the American College of Medical Genetics and 36 Genomics (ACMG) into a quantitative Bayesian point system enables empirical validation of 37 strength of evidence assigned to evidence criteria. Here, we derived a maximum likelihood 38 estimate (MLE) model that converts frequentist odds ratios calculated from case-control data to 39 proportions pathogenic and applied this model to functional assays, alone and in combination 40 with, computational tools across several domains of BRCA1. Furthermore, we defined 41 exceptionally conserved ancestral residues (ECARs) and interrogated the performance of 42 assays and tools at these residues in BRCA1. We found that missense substitutions in BRCA1 43 that fall at ECARs are disproportionately likely to be pathogenic with effect sizes similar to that 44 of protein truncating variants. In contrast, for substitutions falling at non-ECAR positions, 45 concordant predictions of pathogenicity from functional assay and computational tool fail to 46 meet the additive assumptions of strength in ACMG guidelines. Thus, collectively, we conclude 47 that strengths of evidence assigned by expert opinion in the ACMG guidelines are not 48 universally applicable and require empirical validation.

49

50 **INTRODUCTION**:

ClinVar recently celebrated its 10th anniversary. In that time, as clinical sequencing has 51 52 become more prevalent, the number of variants cataloged has grown from approximately 53 27,000 to well over 2 million. Of these 2 million variants, approximately 1.3 million are single 54 nucleotide missense variants (excluding synonymous and nonsense variants), of which roughly 55 75% remain unclassified (~990,000 variants)¹. Realizing the full potential of clinical genetic 56 sequencing relies on the ability to accurately and efficiently classify these variants into a realistic 57 continuum from pathogenic to benign. To that end, many multiplexed assays of variant effect 58 (MAVE) and computational tools have been developed. However, the accuracy of these assays 59 and tools, used independently and in combination with one another, towards classifying novel 60 variants identified during sequencing remains to be established.

61 In 2015, the American College of Medical Genetics and Genomics (ACMG) and the 62 Association for Molecular Pathology (AMP) published guidelines that relied on expert opinion to 63 assign strength of evidence to the various evidence criteria used in sequence variant classification². Subsequently, this approach was found to be compatible with a Bayesian point 64 65 system where the qualitative assessments of evidence strength categories (supporting, moderate, strong, etc.) were converted to quantitative assertions of odds of pathogenicity (OP) 66 67 ^{3, 4}. Shifting to the Bayesian point system makes possible objective evaluation of the strength of 68 evidence the various evidence criteria actually provide. For example, it was recently 69 demonstrated that several computational tools exceeded the qualitative threshold of 70 "supporting" evidence in favor of benignity or pathogenicity and were able to provide 71 "moderate", and in some cases "strong" evidence in favor of benignity or pathogenicity ⁵. 72 In the 2015 ACMG/AMP guidelines, well-established functional assays were gualitatively assigned the ability to provide "strong" evidence in favor of pathogenicity or benignity ⁶. In the 73 74 Bayesian point system, this translates to +4 points (18.7:1 odds in favor of pathogenicity) or -4 75 points (0.053:1 odds in favor of pathogenicity). Yet, limited work has been performed to

76 quantitatively evaluate the strength of evidence that functional assays provide. As these assays 77 are not a direct measure of human health, an important step towards applying a specific 78 functional assay's results to variant classification is validation of the assay's calibration against 79 human subjects' data from the disease in guestion. 80 Furthermore, the 2015 guidelines provided combining rules that prescribed combinations 81 of different categories of evidence that could move a variant towards classification as 82 pathogenic or benign. Implicit in the original guidelines, and explicitly stated in the subsequent 83 work that transformed the guidelines into a Bayesian framework, is the idea that combining 84 evidence changes the estimate of a sequence variant's probability of pathogenicity. In a previous publication⁷, we noted that a majority of variants in the BRCA1 RING domain could be 85 86 classified by using computational predictions (ACMG codes: PP3/BP4), whether or not a variant 87 fell at a canonical residue (ACMG code: PM1), functional assay predictions (ACMG codes: 88 PS3/BS3), and minimal human subjects observational data (ACMG codes: PS4, PM2, BS1). 89 This led to our conclusion that validation work is needed to ensure that the strength assigned to 90 these types of evidence was accurate and that addition of Bayesian points associated with 91 these evidence types was the correct mathematical operation. 92 As a step towards an empirical test, we derive a maximum likelihood estimate (MLE) 93 expression for the proportion of variants that are pathogenic within an analytically defined pool. 94 This model transforms odds ratios (OR) from human subjects' case-control data into a 95 proportion pathogenic which can then be used to objectively test the strength of evidence a 96 particular category of evidence provides. Subsequently, we demonstrate two important 97 applications for such a model using case-control data from BRCA1 as a test case. First, we use 98 our model to determine if evidence from several functional assays developed for BRCA1 99 generate the strength of evidence assumed in the 2015 ACMG/AMP guidelines. Second, we 100 explore the impact of combining functional assay, canonical residue (which we rename 101 "exceptionally conserved ancestral residues" (ECARs)), and computational tool data to see if

102	doina so	changes the	proportion	pathogenic of	of analytical	I subsets of	f variants in a way	v that
	aonig 00							,

103 matches the additivity expectations set forth in the Bayesian adaptation of the 2015

104 classification guidelines (Figure 1). Such an approach allows for the quantitative validation of

- 105 the qualitative assumptions proposed in variant classification guidelines, a step that is currently
- 106 lacking for many evidence criteria used in variant classification.

107 METHODS:

108 Maximum Likelihood Estimate of Proportion Pathogenic

109 In addition to the assumptions in the Bayesian point system ($OP = 81 \frac{ACMG \ points}{6}$, prior

probability of pathogenicity = 0.102, points are log odds and therefore additive), this approach

- 111 relies on several other assumptions:
- 1. The OR of a pool of truncating variants in loss of function susceptibility genes
- provides a "standard candle" by which one can measure the magnitude of effect of agiven analytically defined pool of variants.
- 115 2. An analytically defined pool of variants with an OR similar to that of a pool of
- 116 truncating variants consists almost entirely of variants that are pathogenic with an
- 117 effect size approximately equal to that of the truncating variants.
- 3. An analytically defined pool of variants with an OR near 1.0 consists almost entirelyof benign variants.
- 120 4. Analytically defined pools of variants with an OR between 1.0 and the OR of
- 121 truncating variants can be modeled as a two-component mixture of benign and
- 122 pathogenic variants. This assumption is debatable, but importantly, is also testable.
- 123 The full derivation of the maximum likelihood estimate model is presented in
- supplemental methods. In brief, our model estimates the proportion of observed variants that
- are pathogenic, q, from the proportion of all variants that are pathogenic, p, the number of
- 126 cases, *n*, the number of controls, *m*, the population frequency of disease among individuals who

127 do not carry a pathogenic variant, δ , and the frequency of disease among individual who are 128 carriers of a pathogenic variant, δ_1 , as shown in Equation 1:

129
$$\hat{q} = \frac{\hat{p} \left[n\hat{\delta}(1-\delta_1) + m(1-\hat{\delta})\delta_1 \right]}{\hat{p} \left[n\hat{\delta}(1-\delta_1) + m(1-\hat{\delta})\delta_1 \right] + (1-\hat{p})\hat{\delta}(1-\hat{\delta})(n+m)}$$
(1)

130

In addition to the variables listed above, our MLE model requires input values for an odds ratio threshold at which all variants are assumed to be pathogenic. For the odds ratio threshold in our analysis, truncating variants observed in our case-control data set were tabulated and a frequentist odds ratio was calculated for this group of variants (21.6, 95% CI: 16.9-27.7). To evaluate the prediction of benign variants we used an alternative OR ceiling chosen to match the threshold of moderate risk variants (OR = 2.0), which we calculated to be inflated to 4.4 in our family history enriched case-control dataset ⁸.

The general population frequency of breast cancer that we used in our analysis was
 0.125, as stated in the 2024 update of Cancer Statistics ⁹.

140

141 Identification of Exceptionally Conserved Ancestral Residues in BRCA1 / BARD1

142 To find evolutionarily distant BRCA1/BARD1 homologs, we started with two alignments, 143 one of the RING domains of BRCA1 and BARD1 from Homo sapiens and Strongylocentrotus 144 purpuratus and a second of the corresponding tandem BRCT (tBRCT) domains. These 145 alignments were prepared using the structure-guided 3D-Coffee/Expresso mode from the Tcoffee suite of sequence alignment tools ^{10, 11}. The two resulting alignments were used with 146 147 hmmsearch to scan phylogenetically defined subsets of the reference proteome database maintained at the HMMER website ¹². Hits were defined as gene models with high-scoring 148 149 matches to both the RING and tandem BRCT alignments.

At the first round, hits from Placozoa and single celled Holozoans were included, the alignments rebuilt, and then trimmed back to include clear BRCA1 and BARD1 orthologs from

152 *Trichoplax* and *Salpingoeca*. The process was iterated to obtain and include homologs from the 153 Fungi and then reiterated to obtain and include homologs from three additional eukaryotic

154 supergroups: Archaeplastida, SAR, and Discoba.

155 To prepare the final alignments and then define exceptionally conserved ancestral 156 residues (ECARs), we stratified the hits into a group of BARD1 and relatively BARD1-like hits 157 and a second group of BRCA1 and relatively BRCA1-like groups; ambiguous hits were placed in 158 the BRCA1-like group. As before, RING and tBRCT alignments were prepared using 3D-159 Coffee/Expresso. Then the BRCA1 and BARD1 alignments were aligned to each other by 160 introducing gaps across the whole BRCA1 or whole BARD1 alignment, i.e., without modifying 161 the within-group alignments. The tBRCT alignments were then appended to the RING domain 162 alignments. Finally, ECARs were defined as (a) positions that were invariant in our existing 163 metazoan BRCA1 and BARD1 alignments used with Align-GVGD^{13, 14}, and either (b) also 164 invariant in the new multi-supergroup alignments or (c) had just one conservative substitution 165 (i.e., Grantham Variation <65) in the new multi-supergoup alignment.

166

167 <u>Functional Assay Results and Computational Predictions</u>

168 Functional assay scores were obtained from three separate assays that interrogate 169 missense variants in various domains of BRCA1. These assays were: the 2018 Findlay et al. 170 saturation genome editing (SGE) assay that interrogated missense and splice junction variants 171 in the RING and BRCT domain of BRCA1¹⁵, the 2022 Clark et al. mammalian-2-hybrid (M2H) 172 assay performed by our laboratory that evaluated missense variants in the RING domain of BRCA1⁷, and the 2023 Nagy et al. homology-directed repair (HDR) assay that evaluated 173 missense variants in the coiled-coil domain of BRCA1¹⁶. Scores for these assays were 174 downloaded from MaveDB (SGE and M2H)¹⁷ or from the publication ¹⁶. Thresholds for 175 176 functional, indeterminate and non-functional variants were used as defined by the relevant 177 publication.

178	Computational tool scores for BayesDel no-AF ¹⁸ , REVEL ¹⁹ , and VEST4 ²⁰ were
179	obtained from the database for Non-synonymous Functional Predictions (dbNSFP) via
180	Ensembl's web-based Variant Effect Predictor (VEP) ^{21, 22} . Computational scores for MutPred2
181	were obtained by downloading a local copy of the software ²³ . Scores for AlphaMissense were
182	downloaded from the original publication ²⁴ . Scores for Align-GVGD (A-GVGD) ^{25, 26} were
183	obtained from agvgd.hci.utah.edu using the Human to Sea Urchin alignment. Thresholds for
184	pathogenic and benign for AlphaMissense, BayesDel, MutPred2, REVEL, and VEST4 were the
185	supporting pathogenic and supporting benign thresholds from recent calibrations of these tools ^{5,}
186	²⁷ Align-GVGD, predictions with a score of C0 were interpreted as predicted benign and
187	predictions with a score of C65 were interpreted as predicted pathogenic with all other scores
188	being indeterminate.
189	
190	Estimate of ACMG Points
191	We interpreted the MLE proportion pathogenic as a posterior probability, PP
192	(represented as q in the supplemental information and Equation 1), of the variant being

pathogenic and we thus converted this estimate to the appropriate ACMG point via an OP using a prior probability (P₁) of 0.102 and Equations 2 and 3 below. Both equations and the prior probability come from Tavtigian et al. ⁴. When assigning ACMG points from the estimated proportion pathogenic, the points that could be awarded were limited to the maximum values prescribed in the ACMG guidelines ^{2, 4}.

198
$$PP = (OP \times P_1) \div [(OP - 1) \times P_1 + 1]$$
(2)

199

$$OP = 81 \frac{ACMG \ points}{6} \tag{3}$$

- 200
- 201

202 Case and Control Count Sources and Odds Ratio Calculations

203 Human subjects' data were obtained from Ambry Genetics and Myriad Genetics. Control 204 counts are from the non-cancer cohort of gnomAD v2 exomes and gnomAD v3 genomes. 205 The Ambry dataset initially included data generated by Ambry Genetics from multi-gene 206 sequencing panels for 165,031 individuals "exempted from review by the Western Institutional Review Board" ²⁸. Filters were applied to remove those individuals without breast or ovarian 207 208 cancer, individuals who lacked BRCA1 sequence data, individuals of Ashkenazi Jewish 209 ancestry, and individuals with pathogenic or likely pathogenic variants in TP53, BRCA2, and 210 PALB2. This resulted in a final dataset of 91,367 individuals, of which 2,930 had variants in 211 BRCA1. Of these 2,930 individuals, 498 had missense variants that fell within the RING (amino 212 acids 1-100), coiled-coil (amino acids 1.280-1,576), or BRCT domain (amino acids 1.650-213 1,863).

214 The Myriad dataset initially included data generated by full-sequence BRCA1/2 tests 215 performed by Myriad Genetics from 60,607 individuals. For these, a test request form must have 216 been completed by the ordering health care provider, and the form must have been signed by an appropriate individual indicating that "informed consent has been signed and is on file" ^{13, 28,} 217 218 ²⁹. Filters were applied to remove those individuals without breast or ovarian cancer, individuals 219 who lacked BRCA1 sequence data, individuals of Ashkenazi Jewish ancestry, and individuals 220 with pathogenic or likely pathogenic variants in BRCA2. This resulted in a final dataset of 35,088 221 individuals, of which 4,005 had variants in BRCA1. Of these 4,005 individuals, 524 had 222 missense variants that fell within the RING, coiled-coil, or BRCT domain.

The gnomAD dataset is a composite of v2 non-cancer exomes and v3 non-cancer genomes that initially included 192,502 individuals. Filters were applied to remove individuals of Finnish or Ashkenazi Jewish ancestry and to remove common missense variants (allele frequency > 0.000271). This resulted in a final dataset of 169,933 individuals, of which 955 had missense variants that fell within the *BRCA1* RING, coiled-coil, or BRCT domain.

228 Combining these datasets resulted in a final dataset of 126,455 breast and ovarian 229 cases from Ambry and Myriad and 169,933 controls from gnomAD v2 and v3. Ethnicity for this 230 dataset was split into four groups: non-Finnish European, Ashkenazi Jewish, Finnish, and all 231 others. As stated previously, Ashkenazi Jewish and Finnish individuals were removed due to 232 strong founder effects in these populations.

After filtering, the data for *BRCA1* were formatted into a table that indicated the ethnicity of the individual, whether an individual was a case or control, how the variant was classified by each functional assay and computational tool, and whether the variant fell at an ECAR. Logistic regression was performed using Stata 17.0 (Statacorp) to calculate frequentist odds ratios. Proportions pathogenic were calculated using a custom R script. Following logistic regression, the Wald test was performed to determine statistical significance between strata in each

analysis.

240

241 **RESULTS**:

242 Exceptionally Conserved Ancestral Residues in BRCA1 / BARD1

243 BRCA1, BARD1, and homologs that have been studied in the Archaeplastida are 244 thought to have evolved from a common ancestor gene with a 5' RING domain and 3' tandem 245 BRCT (tBRCT) domain that was present in an ancient eukaryote before the divergence of Amorphea and Archaeplastida³⁰. Protein multiple sequence alignment (PMSA) based 246 247 hmmsearch ¹² identified clear BRCA1 and BARD1 orthologs in Trichoplax and more distantly 248 related single-celled members of Holozoa, plus homologs (some of which may be true 249 orthologs) in the Holomycota, Archaeplastida, SAR, and Discoba. Although the root of the eukaryotic phylogeny remains unclear ^{31, 32}, the resulting PMSA should be sufficient to identify 250 251 positions in human BRCA1 and BARD1 where the amino acid present in the human sequence 252 has been inherited identical by descent from a common ancestor of the Amorphea and is under 253 constraint in 2-3 additional eukaryotic supergroups. We identified 14 such residues: the 8

residues that define the C3HC4 RING motif plus 6 additional residues in the tBRCT domain
(Table 1, Figure S1), and hereafter refer to them as Exceptionally Conserved Ancestral
Residues (ECARs).

257 Of the 82 possible snMSs at ECARs, 78 resulted in a non-functional assay result via the 258 SGE assay. The four exceptions were C24F, C61R, T1700S (which was not interrogated in the 259 SGE assay), and W1718S. C24F, C61R, and W1718S had indeterminate results in the SGE 260 assay, however, C24F and C61R were scored as loss of function in the M2H assay.

Using the pathogenic strong thresholds established in Pejaver et al, we also tabulated the number of substitutions at ECARs that were extreme enough to receive +4 ACMG points from computational tools (Table 1). MutPred2 predicted 0 of the possible ECAR substitutions to be extreme enough to receive +4 ACMG points. BayesDel predicted 56 of the 82 possible substitutions to be extreme enough for +4 ACMG points, and these constituted 56 of the 73 such RING and tBRCT +4 results called by BayesDel. AlphaMissense, REVEL, and VEST4 had totals that fell between MutPred2 and BayesDel.

A separate analysis was performed using the BayesDel threshold prescribed in the ENIGMA BRCA1 Variant Curation Expert Panel (VCEP) guidelines (≥ 0.28) as well as for Align-GVGD using C65 as a pathogenic prediction threshold³³. Under these parameters, many more of the ECARs identified in the tBRCT domains were predicted to be pathogenic (Table 1). A summary of computational tool performance at ECAR positions and individual scores for each substitution are available in Supplementary Table 1.

274 <u>Functional Assay Performance</u>

In our initial analysis, we used an OR threshold set to that of the OR of nonsense
substitutions observed in our case control dataset, which was 21.6 (95% CI: 16.9-27.7). The
results of our analysis of functional assay performance using this OR threshold are presented in
Table 2. As stated in the Methods section, ACMG points awarded are limited to the maximum

number of points outlined in the ACMG guidelines and subsequent transformation to a Bayesianframework.

281 In the M2H assay, which interrogates variants in the RING domain of BRCA1, variants 282 that were functional and were observed in our case control dataset yielded an adjusted OR 283 close to 1 (1.21, 95% CI: 0.85-1.72) indicating a group of variants composed almost entirely of 284 benign variants. The proportion pathogenic for this group was estimated to be 0.01 which 285 translates to -3 points in the ACMG points system. There were insufficient observations for 286 variants that were categorized as indeterminate to compute an OR or a proportion pathogenic. 287 The group of all variants that were non-functional and observed in our dataset had an adjusted 288 OR of 22.6 (95% CI: 12.9-39.5) which is similar to that of nonsense substitutions in our dataset. 289 indicating a group consisting of mostly pathogenic variants. This analytical subset had a 290 proportion pathogenic of 1.00, which would be assigned the full +4 points that are available for 291 non-functional assay results in the ACMG guidelines.

292 In addition to evaluating the strength of evidence of a single evidence category, our 293 model can also test the strength of combined evidence categories. To this end, we stratified the 294 non-functional variants from the M2H assay into two groups: variants that fell at the ECARs we 295 identified from the PMSA, and all other residues (ACMG code: PM1). For variants that were 296 non-functional and fell at an ECAR, the computed OR was 24.8 (95% CI: 13.5-45.6), slightly 297 higher than the group of all non-functional variants and indicating a subset of variants with 298 similar risk to that of truncating variants. The computed proportion pathogenic remained at 299 1.00. Combining the +4 points from functional assay and +2 points available from ECARs 300 (PM1), results in +6 points for this group of variants. Thus, using these two evidence criteria 301 alone, these variants reach the likely pathogenic threshold.

The computed OR for non-functional variants that fell at other residues was 9.89 (95% CI: 2.23-43.9), indicating that this group of variants confers less risk than those that are nonfunctional and fall at an ECAR. The proportion pathogenic for the non-functional variants that

fell at other residues was 0.74, sufficient for +4 points from functional assay. In the absence ofother evidence, this group would remain VUS.

307 The SGE assay, which evaluated variants across the RING and tBRCT domains of 308 BRCA1, had similar results to the M2H assay. However, the group of variants that were 309 functional via SGE yielded an OR close to 1 (0.80, 95% CI: 0.64-1.00) and a proportion 310 pathogenic of 0.00, which would qualify for the full -4 points available from a functional assay 311 result. For variants that were non-functional, the SGE assay had an OR of 16.3 (95% CI: 11.6-312 27.7) and a proportion pathogenic of 0.88 which would confer the full +4 points for these 313 variants. Stratification of non-functional variants at ECARs versus non-functional variants at 314 other residues again demonstrates that non-functional variants at ECARs have enough strength 315 of evidence to reach the likely pathogenic threshold. The ORs for these groups were 26.2 (95% 316 CI: 14.3-48.1) and 12.0 (95% CI: 7.91-18.1), respectively, with a χ^2 p-value of 0.037. Non-317 functional variants at ECARs had a proportion pathogenic of 1.00 which equates to +6 points. 318 Variants that are non-functional and fall at other residues have a proportion pathogenic of 0.71. just above the threshold required for +4 points; moreover, the χ^2 result provides evidence that 319 320 the two groups are indeed distinct.

321 Whereas the M2H and SGE assays largely confirmed the assumptions of strength of 322 evidence in the ACMG guidelines, the results from the HDR assay in the coiled-coil domain of 323 BRCA1 show a different result. The ORs for the functional and non-functional groups were 1.32 324 (95% CI: 0.76-2.29) and 1.48 (95% CI: 0.87-25.2) respectively, indicating that both groups of 325 variants are largely benign. The group of functional variants had a calculated proportion 326 pathogenic of 0.05 which would only justify -1 point. The group of non-functional variants had a 327 proportion pathogenic of 0.06 which is insufficient to justify evidence in either direction (towards 328 pathogenicity or benignity) and thus 0 points. It is noted that there were few observations in our 329 case-control dataset that both fell within this domain and were included in the functional assay.

Additionally, many of the variants interrogated by this assay do not appear to be attainable via a single nucleotide substitution to the canonical BRCA1 transcript, which is the type of substitution that is the primary focus of this analysis.

333 Due to these limitations, we performed a separate analysis focusing on structurally 334 informed predictions of damage to coiled-coil interactions at the alpha helix spanning amino

acids 1,400-1,418, i.e., non-conservative substitutions at the helix *a* and *d* positions plus any

substitutions to proline falling in the same interval. With only one observation in a case

337 (p.L1407R) against four control observations (one each for p.M1400K, p.L1404R, p.L1407H,

and p.L1414P), the observational evidence weighs against the hypothesis that missense

339 substitutions in this domain are pathogenic (Table 2, final line).

340 Combining SGE Functional Results and Computational Predictions

341 To explore the impact of combining functional assay results and computational tool

342 predictions we stratified variants from the SGE assay by computational prediction (pathogenic,

indeterminate, and benign) from six computational tools (Align-GVGD, AlphaMissense,

BayesDel, MutPred2, REVEL, and VEST4) using thresholds outlined in Pejaver *et al.* or those

345 stated in the Methods section ⁵. This analysis was performed only on results from the SGE

assay which interrogated both the RING and BRCT domains of *BRCA1* and thus had sufficient

347 observations for stratification.

348 <u>Combining Non-functional Assay Results with Computational Predictions for Substitutions</u>

349 Falling at Non-ECAR Positions

The OR for the group of variants that were categorized as non-functional via the SGE assay and did not fall at ECARs was 12.0 (95% CI: 7.91-18.1) with a proportion pathogenic of 0.71, just reaching +4 ACMG points, as stated previously. By stratifying these variants by computational prediction, we can evaluate the effect of combining functional assay and computational prediction data toward variant classification (Table 3). It should be noted that if the computational predictions unanimously agreed with the functional assay result, the OR,

estimated proportion pathogenic, and ACMG points would remain unchanged after adding in
evidence from computational tools. Thus, the true utility of computational predictions in this
analysis stems from the ability of the computational tool to accurately disagree with – and
thereby stratify – the functional assay result.
Of the computational tools included in our analysis, pathogenic predictions from

BayesDel and REVEL did not increase the OR or the estimated proportion pathogenic when combined with the non-functional assay data. It is noted that the breakdown of predictions for BayesDel and REVEL are the same. This is not unexpected as both are meta-callers, incorporating predictions from individual callers into a weighted overall score, and share several of the same individual components ^{18, 19}.

366 On the other hand, pathogenic predictions from Align-GVGD, AlphaMissense, MutPred2, 367 and VEST4 did increase the OR and thus the estimated proportion pathogenic from that of the 368 functional assay result, albeit not sufficiently to meet the expected value of +5 ACMG points.

369 Additionally, Align-GVGD, AlphaMissense, MutPred2, and VEST4 decreased the ORs 370 and estimated points for variants that were non-functional via assay and either indeterminate or 371 benign by computational prediction. Notably, Align-GVGD and MutPred2 yielded results in the 372 expected descending proportion pathogenic order from non-functional computationally 373 pathogenic to non-functional computationally benign. For Align-GVGD, the 23 unique variants 374 (106 case-control observations) that were non-functional via assay and predicted pathogenic 375 had an OR of 14.9 (95% CI: 7.97-28.0) and a proportion pathogenic of 0.79, which equates to 376 +4 ACMG points. The 20 unique variants (82 case-control observations) that were non-377 functional via assay and computationally indeterminate had an OR of 10.9 (95% CI: 5.72-20.6) 378 and a proportion pathogenic of 0.68, which equates to +3 ACMG points. Finally, the 15 unique 379 variants (20 case-control observations) that were non-functional and predicted benign had an 380 OR of 6.80 (95% CI: 2.24-20.6) and a proportion pathogenic of 0.49, which equates to +2

381 ACMG points. Corresponding results for the other computational tools are summarized in Table382 3.

383 Combining Functionally Normal Assay Results with Computational Predictions for Substitutions

384 Falling at Non-ECAR Positions

For the analysis of variants that were functionally normal via SGE and did not fall at ECARs, we used an alternative OR ceiling at the threshold for moderate risk variants (OR = 2 in a general population, which is inflated to approximately 4.4 in our dataset) to evaluate evidence against pathogenicity. For the SGE assay, functional variants had an OR of 0.8 (95% CI: 0.64-1.00) and an estimated proportion pathogenic of 0.00, sufficient for the -4 ACMG points allowable from functional assays. The results of stratification by computational tool are presented in Table 4.

Compared to other computational tools, BayesDel and REVEL made few predictions of benignity even though this group of variants were functional via the assay. Interestingly, REVEL did not predict any of the variants in this dataset to be benign and BayesDel only predicted five unique variants to be so. For REVEL, the ORs for variants predicted to be pathogenic or indeterminate remained close to 1.0, 1.08 (95% CI: 0.77-1.52) and 0.49 (95% CI: 0.36-0.68), respectively.

398 Excepting MutPred2 and REVEL, pathogenic predictions from the other computational 399 tools elevated the OR, proportion pathogenic, and ACMG points for the subset of functional 400 variants from the assay (see Table 4). Discordance between functional assay and 401 computational tool is of sufficient magnitude to move variants in these analytical subsets from 402 likely benign (-1 to -6 ACMG points) up to VUS (0-5 ACMG points). Furthermore, predictions of 403 pathogenicity from Align-GVGD, AlphaMissense, BayesDel-VCEP, and VEST4 on functionally 404 normal variants created subsets that were statistically significantly distinct from benign 405 predictions on functionally normal variants.

Of particular note is the series of ORs, proportions pathogenic, and ACMG points that
result from stratification by Align-GVGD, AlphaMissense, and BayesDel. These tools were the
only ones of those evaluated in this study that yielded three appropriately ordered analytical
subsets for functional variants from the SGE assay. The ORs for pathogenic, indeterminate,
and benign Align-GVGD predictions were 2.53 (95% CI:1.00-6.38), 1.45 (95% CI: 0.93-2.26),
and 0.58 (95% CI: 0.44-0.77) respectively. The corresponding proportions pathogenic were
0.32, 0.10, and 0.00, corresponding to ACMG points of 1, 0, and -5 respectively.

413 **DISCUSSION**:

414 In the above analysis, we provide an MLE model that links the OR from a case-control 415 analysis to an estimate of the proportion of variants that are pathogenic and thereby to the odds 416 of pathogenicity and corresponding ACMG points. We also defined and identified ECARs within 417 the RING and tBRCT domains of BRCA1. We then demonstrated important use cases of our 418 MLE model in evaluating the strength of evidence for several functional assays alone and in 419 combination with ECAR data and computational tool predictions, as summarized in Figure 2. 420 This work takes an important step in the ability to empirically test whether the assertions of the 421 strength of evidence for different evidence types, and the combinations thereof, proposed in the 422 2015 ACMG/AMP guidelines are valid. And it does so in a way that takes account of effect size 423 while avoiding the circularities inherent in analyses that are based on re-call.

424 We analyzed the performance of several computational tools at the ECARs that were 425 identified through our multi-supergroup PMSA. While some tools, especially AlphaMissense, 426 BayesDel, and REVEL, seemed to be "aware" of the ECARs in the RING domain, far fewer 427 substitutions at ECARs in the tBRCT domain had high enough scores to receive +4 ACMG 428 points. Additionally, there was variability between tools in the number of ECARs that received 429 extreme enough scores to award +4 ACMG points (0 substitutions at ECARs received +4 from 430 MutPred2, while 56 did from BayesDel), even though most computational tools incorporate 431 evolutionary conservation into their predictions. This discrepancy may arise due to limitations in

432 creating deep, multi-supergroup PMSAs using currently available automated alignments. By
433 manually curating our alignment, we were able to include sequences that contained inserts of
434 various sizes between the RING and tBRCT domains that would likely be discarded by
435 automated approaches.

436 From our analysis of the strength of evidence that functional assays provide, we 437 conclude that functional assays can indeed reach a quantitative threshold that aligns with the 438 recommendations outlined in the ACMG guidelines, in both the benign and pathogenic 439 directions. However, the strength of evidence can differ in the pathogenic and benign directions 440 and not all assays validate as a predictor of pathogenicity. For example, variants with functional 441 results from the M2H assay in the RING domain of BRCA1 fell just short of the OP threshold for 442 -4 points, while non-functional results provided sufficient evidence for +4 points. Furthermore, 443 our structurally informed analysis of predicted loss of function substitutions in the core alpha 444 helix of the BRCA1 coiled coil domain (amino acids 1,400 – 1,418) weigh against the hypothesis 445 that missense substitutions in this domain can be pathogenic. Thus, this study provides further 446 evidence that careful evaluation of functional assays is required prior to their use in clinical 447 settings and that +/-4 points should not be assigned carte blanche⁶.

448 For substitutions that fell at ECAR positions, we found that predictions of pathogenicity 449 from functional assay are additive in a manner consistent with ACMG guidelines (i.e +4 points 450 from PS3 and +2 points from PM1 = +6). Furthermore, these variants had an effect size similar 451 to that of truncating variants. However, for non-functional substitutions that fell at non-ECAR 452 positions, we found that concordant predictions of pathogenicity from functional assay and 453 computational tool are not additive as proposed in the ACMG guidelines (i.e +4 points from PS3 454 and +1 point from PP3 = +5). Specifically, we found that none of the tools included in this 455 analysis were able to raise the proportion pathogenic as expected and these pools of variants 456 only provided enough strength of evidence for +4 points. However, for functionally normal 457 variants in the assay, concordant predictions in the benign direction from several computational

tools did meet the ACMG combining expectations (i.e -4 points from BS3 and -1 point from BP4
= -5).

460 Conflicting predictions between functional assay and computational tools were able to 461 modulate effect size, estimated proportions pathogenic and ACMG points for the resulting 462 analytical subsets. For substitutions that were non-functional via the SGE assay and fell at non-463 ECAR positions, benign or indeterminate predictions from several computational tools were 464 found to deprecate the evidence from the functional assay. For example, after stratification by 465 Align-GVGD, less than half (23/58) of the observed variants retained a sufficient proportion 466 pathogenic for +4 ACMG points. For substitutions that were functional via the SGE assay, 467 pathogenic or indeterminate predictions from several computational tools created statistically 468 different effect sizes after stratification.

469 While the ACMG expectations were not met for all instances of functional assay and 470 computational tool combinations, we note that two tools, Align-GVGD and MutPred2, were able 471 to produce appropriately ordered series of ORs, proportions pathogenic, and ACMG points for 472 predicted pathogenic variants. On the benign side, only Align-GVGD and AlphaMissense yielded 473 the appropriately ordered series of ORs, proportions pathogenic, and ACMG points. Thus Align-474 GVGD was the only computational tool that was able to appropriately stratify non-functional and 475 functional results in both the pathogenic and benign directions. While Align-GVGD was not 476 explicitly trained on BRCA1, it was optimized for this gene. Therefore, future studies will need 477 to interrogate the performance of this and other tools on a diverse set of genes.

This study focused on functional assay results individually and in combination with ECARs and computational tool predictions, however, this method can be applied to any classifier or combination of classifiers. We chose *BRCA1* as a test case, in part, because of the robust case-control dataset that is available for this gene. In instances where case-control data may be more limited, a similar analysis could be conducted by pooling a defined set of genes and evaluating the ability of the classifier in guestion to generate ordered series of ORs with

appropriate effect sizes. Effective evaluation of variant effect predictors will increasingly rely on
availability of case data to match the publicly available control data that can obtained from
sources such as gnomAD, the UK Biobank, and the All of Us Projects.

Additionally, this analysis provides a way of evaluating the strength of evidence that a particular classifier, or combinations of classifiers, provides in relation to an analytical subset of variants (i.e predicted benign, predicted pathogenic). It does not evaluate the pathogenicity of an individual variant. Thus, even though an assay's predictions or combinations of an assay and computational tool perform well in this analysis, analytical subsets of variants may contain individual variants that differ in their unique role in disease from the group at large.

Beyond the findings from this study, further considerations may need to be adapted over time and depending on use case. For example, our analysis looks at two possible OR thresholds that one could use, that of nonsense variants in our dataset (OR = 21.62) and the ENIGMA-defined threshold for moderate risk variants in our dataset (OR = 4.4). While the resolution of which threshold to use is beyond the scope of this work; we note that careful selection of a standard candle by which to interpret subsets of variants will be critical.

499 These findings are important to bear in mind as assays and other tools are validated for 500 use in variant classification. Often, functional assays and computational tools are validated by 501 re-call, using the raw classifications of variants to assess the performance of the new assay or 502 tool. It is known that this strategy leads to overly confident evaluations of variant effect 503 classifiers due to circularities inherent in training and validation datasets ³⁴. Furthermore, it may 504 be the case that variants that are already securely classified are different from variants that 505 remain to be classified and may have other characteristics, such as disproportionately falling at 506 ECARs, that potentially inflate the strength of evidence the new assay or tool naively seems to 507 provide. Therefore, it is important to conduct analyses that assess effect size as a validation 508 step – and be prepared to modify or reject calibrations that do not reach the required effect size.

509 This study provides a means to do this without the need for re-call, provided there are sufficient 510 case-control or family history data available.

511 In 2018, we proposed a bidirectional feedback model wherein empirical measurements 512 of strength of evidence steadily improve the rigor of variant classification ⁴ thereby providing 513 stepping stones towards clinical validity. This work provides a practical model that can be used 514 to achieve that end. Our MLE model assumes an underlying two-component mixture model in 515 which stratification would yield subsets of variants with effect size similar to that of truncating 516 variants (for loss of function susceptibility genes) and a subset with an effect size similar to 517 benign variants. However, this Platonic Form of clear-cut analytical subsets may not be what is 518 observed in practice. Indeed, in our analysis, variants that had non-functional assay results and 519 did not fall at ECARs had ORs above the benign threshold but below the OR for truncating 520 variants. Future work, therefore, should focus on strategies to further resolve variant 521 stratification on the continuum from benign to pathogenic. 522 The combination of functional assays and computational tools have been heralded as the path 523 forward to resolve variant classification uncertainty due to their ability to predict the outcomes of large sets of variants ^{7, 35, 36}. However, as shown in this study, current assays, tools, and their 524 525 combinations may not meet the quantitative strength assigned in classification guidelines or 526 published calibration studies. Additional refinement, careful calibration, and rigorous validation 527 of variant classifiers is critical to ensure that those who use these tools are aware of the strength 528 of evidence they provide.

529 **ACKNOWLEDGEMENTS**:

- 530 We would like to thank Marcy Richardson, Tina Pesaran, Colin Young, and Steven Harrison
- 531 from Ambry Genetics for thoughtful discussion and database support. We would also like to
- thank AC Tan, Jay Gertz, and Pinar Bayrak-Toydemir for thoughtful reading and comments on
- 533 the manuscript.
- 534
- 535
- 536

537 **REFERENCES**:

- 538 (1) Landrum, M. J.; Lee, J. M.; Riley, G. R.; Jang, W.; Rubinstein, W. S.; Church, D. M.; Maglott,
- 539 D. R. ClinVar: public archive of relationships among sequence variation and human phenotype.
- 540 *Nucleic Acids Res* **2014**, *42* (Database issue), D980-985. DOI: 10.1093/nar/gkt1113 From NLM
- 541 Medline.
- 542 (2) Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W. W.; Hegde,
- 543 M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence
- variants: a joint consensus recommendation of the American College of Medical Genetics and
- 545 Genomics and the Association for Molecular Pathology. *Genet Med* **2015**, *17* (5), 405-424. DOI:
- 546 10.1038/gim.2015.30 From NLM Medline.
- 547 (3) Tavtigian, S. V.; Greenblatt, M. S.; Harrison, S. M.; Nussbaum, R. L.; Prabhu, S. A.; Boucher,
- 548 K. M.; Biesecker, L. G.; ClinGen Sequence Variant Interpretation Working, G. Modeling the
- 549 ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genet Med*

550 **2018**, *20* (9), 1054-1060. DOI: 10.1038/gim.2017.210 From NLM Medline.

- 551 (4) Tavtigian, S. V.; Harrison, S. M.; Boucher, K. M.; Biesecker, L. G. Fitting a naturally scaled
- point system to the ACMG/AMP variant classification guidelines. *Hum Mutat* **2020**, *41* (10),
- 553 1734-1737. DOI: 10.1002/humu.24088 From NLM Medline.
- (5) Pejaver, V.; Byrne, A. B.; Feng, B. J.; Pagel, K. A.; Mooney, S. D.; Karchin, R.; O'Donnell-
- Luria, A.; Harrison, S. M.; Tavtigian, S. V.; Greenblatt, M. S.; et al. Calibration of computational
- tools for missense variant pathogenicity classification and ClinGen recommendations for
- 557 PP3/BP4 criteria. Am J Hum Genet **2022**, 109 (12), 2163-2177. DOI:
- 558 10.1016/j.ajhg.2022.10.013 From NLM Medline.
- (6) Brnich, S. E.; Abou Tayoun, A. N.; Couch, F. J.; Cutting, G. R.; Greenblatt, M. S.; Heinen, C.
- 560 D.; Kanavy, D. M.; Luo, X.; McNulty, S. M.; Starita, L. M.; et al. Recommendations for application

- 561 of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant
- interpretation framework. *Genome Med* 2019, *12* (1), 3. DOI: 10.1186/s13073-019-0690-2 From
 NLM Medline.
- 564 (7) Clark, K. A.; Paquette, A.; Tao, K.; Bell, R.; Boyle, J. L.; Rosenthal, J.; Snow, A. K.; Stark, A.
- 565 W.; Thompson, B. A.; Unger, J.; et al. Comprehensive evaluation and efficient classification of
- 566 BRCA1 RING domain missense substitutions. *Am J Hum Genet* **2022**, *109* (6), 1153-1174. DOI:
- 567 10.1016/j.ajhg.2022.05.004 From NLM Medline.
- 568 (8) Spurdle, A. B.; Greville-Heygate, S.; Antoniou, A. C.; Brown, M.; Burke, L.; de la Hoya, M.;
- 569 Domchek, S.; Dork, T.; Firth, H. V.; Monteiro, A. N.; et al. Towards controlled terminology for
- 570 reporting germline cancer susceptibility variants: an ENIGMA report. J Med Genet 2019, 56 (6),
- 571 347-357. DOI: 10.1136/jmedgenet-2018-105872 From NLM Medline.
- 572 (9) Siegel, R. L.; Giaquinto, A. N.; Jemal, A. Cancer statistics, 2024. *CA Cancer J Clin* **2024**, 74
- 573 (1), 12-49. DOI: 10.3322/caac.21820 From NLM Medline.
- 574 (10) Wallace, I. M.; O'Sullivan, O.; Higgins, D. G.; Notredame, C. M-Coffee: combining multiple
- 575 sequence alignment methods with T-Coffee. *Nucleic Acids Res* **2006**, *34* (6), 1692-1699. DOI:
- 576 10.1093/nar/gkl091 From NLM Medline.
- 577 (11) Armougom, F.; Moretti, S.; Poirot, O.; Audic, S.; Dumas, P.; Schaeli, B.; Keduas, V.;
- 578 Notredame, C. Expresso: automatic incorporation of structural information in multiple sequence
- alignments using 3D-Coffee. *Nucleic Acids Res* **2006**, 34 (Web Server issue), W604-608. DOI:
- 580 10.1093/nar/gkl092 From NLM Medline.
- 581 (12) Potter, S. C.; Luciani, A.; Eddy, S. R.; Park, Y.; Lopez, R.; Finn, R. D. HMMER web server:
- 582 2018 update. *Nucleic Acids Res* 2018, 46 (W1), W200-W204. DOI: 10.1093/nar/gky448 From
- 583 NLM Medline.

- 584 (13) Tavtigian, S. V.; Byrnes, G. B.; Goldgar, D. E.; Thomas, A. Classification of rare missense
- substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. *Hum*
- 586 Mutat 2008, 29 (11), 1342-1354. DOI: 10.1002/humu.20896 From NLM Medline.
- 587 (14) Young, E. L.; Feng, B. J.; Stark, A. W.; Damiola, F.; Durand, G.; Forey, N.; Francy, T. C.;
- 588 Gammon, A.; Kohlmann, W. K.; Kaphingst, K. A.; et al. Multigene testing of moderate-risk
- genes: be mindful of the missense. *J Med Genet* **2016**, *53* (6), 366-376. DOI:
- 590 10.1136/jmedgenet-2015-103398 From NLM Medline.
- 591 (15) Findlay, G. M.; Daza, R. M.; Martin, B.; Zhang, M. D.; Leith, A. P.; Gasperini, M.; Janizek, J.
- 592 D.; Huang, X.; Starita, L. M.; Shendure, J. Accurate classification of BRCA1 variants with
- 593 saturation genome editing. *Nature* **2018**, 562 (7726), 217-222. DOI: 10.1038/s41586-018-0461-
- 594 z From NLM Medline.
- (16) Nagy, G.; Diabate, M.; Banerjee, T.; Adamovich, A. I.; Smith, N.; Jeon, H.; Dhar, S.; Liu, W.;
- 596 Burgess, K.; Chung, D.; et al. Multiplexed assay of variant effect reveals residues of functional
- importance in the BRCA1 coiled-coil and serine cluster domains. *PLoS One* **2023**, *18* (11),
- 598 e0293422. DOI: 10.1371/journal.pone.0293422 From NLM Medline.
- 599 (17) Esposito, D.; Weile, J.; Shendure, J.; Starita, L. M.; Papenfuss, A. T.; Roth, F. P.; Fowler, D.
- 600 M.; Rubin, A. F. MaveDB: an open-source platform to distribute and interpret data from
- 601 multiplexed assays of variant effect. *Genome Biol* **2019**, *20* (1), 223. DOI: 10.1186/s13059-019-
- 602 1845-6 From NLM Medline.
- (18) Feng, B. J. PERCH: A Unified Framework for Disease Gene Prioritization. *Hum Mutat* **2017**,
- 604 38 (3), 243-251. DOI: 10.1002/humu.23158 From NLM Medline.
- 605 (19) Ioannidis, N. M.; Rothstein, J. H.; Pejaver, V.; Middha, S.; McDonnell, S. K.; Baheti, S.;
- Musolf, A.; Li, Q.; Holzinger, E.; Karyadi, D.; et al. REVEL: An Ensemble Method for Predicting

- the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **2016**, *99* (4), 877-885. DOI:
- 608 10.1016/j.ajhg.2016.08.016 From NLM Medline.
- 609 (20) Carter, H.; Douville, C.; Stenson, P. D.; Cooper, D. N.; Karchin, R. Identifying Mendelian
- disease genes with the variant effect scoring tool. BMC Genomics 2013, 14 Suppl 3 (Suppl 3),
- 611 S3. DOI: 10.1186/1471-2164-14-S3-S3 From NLM Medline.
- 612 (21) Martin, F. J.; Amode, M. R.; Aneja, A.; Austine-Orimoloye, O.; Azov, A. G.; Barnes, I.;
- Becker, A.; Bennett, R.; Berry, A.; Bhai, J.; et al. Ensembl 2023. Nucleic Acids Res 2023, 51
- 614 (D1), D933-D941. DOI: 10.1093/nar/gkac958 From NLM Medline.
- 615 (22) Liu, X.; Li, C.; Mou, C.; Dong, Y.; Tu, Y. dbNSFP v4: a comprehensive database of
- 616 transcript-specific functional predictions and annotations for human nonsynonymous and splice-
- 617 site SNVs. *Genome Med* **2020**, *12* (1), 103. DOI: 10.1186/s13073-020-00803-9 From NLM
- 618 Medline.
- 619 (23) Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K. A.; Lin, G. N.; Nam, H. J.; Mort, M.;
- 620 Cooper, D. N.; Sebat, J.; lakoucheva, L. M.; et al. Inferring the molecular and phenotypic impact
- 621 of amino acid variants with MutPred2. Nat Commun 2020, 11 (1), 5918. DOI: 10.1038/s41467-
- 622 020-19669-x From NLM Medline.
- 623 (24) Cheng, J.; Novati, G.; Pan, J.; Bycroft, C.; Zemgulyte, A.; Applebaum, T.; Pritzel, A.; Wong,
- 624 L. H.; Zielinski, M.; Sargeant, T.; et al. Accurate proteome-wide missense variant effect
- 625 prediction with AlphaMissense. *Science* **2023**, *381* (6664), eadg7492. DOI:
- 626 10.1126/science.adg7492 From NLM Medline.
- 627 (25) Tavtigian, S. V.; Deffenbaugh, A. M.; Yin, L.; Judkins, T.; Scholl, T.; Samollow, P. B.; de
- 628 Silva, D.; Zharkikh, A.; Thomas, A. Comprehensive statistical study of 452 BRCA1 missense
- 629 substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet* **2006**, 43
- 630 (4), 295-305. DOI: 10.1136/jmg.2005.033878 From NLM Medline.

- 631 (26) Mathe, E.; Olivier, M.; Kato, S.; Ishioka, C.; Hainaut, P.; Tavtigian, S. V. Computational
- approaches for predicting the biological effect of p53 missense mutations: a comparison of three
- 633 sequence analysis based methods. *Nucleic Acids Res* 2006, 34 (5), 1317-1325. DOI:
- 634 10.1093/nar/gkj518 From NLM Medline.
- 635 (27) Bergquist, T.; Stenton, S. L.; Nadeau, E. A. W.; Byrne, A. B.; Greenblatt, M. S.; Harrison, S.
- M.; Tavtigian, S. V.; O'Donnell-Luria, A.; Biesecker, L. G.; Radivojac, P.; et al. Calibration of
- additional computational tools expands ClinGen recommendation options for variant
- 638 classification with PP3/BP4 criteria. *bioRxiv* 2024. DOI: 10.1101/2024.09.17.611902 From NLM
- 639 PubMed-not-MEDLINE.
- 640 (28) Li, H.; LaDuca, H.; Pesaran, T.; Chao, E. C.; Dolinsky, J. S.; Parsons, M.; Spurdle, A. B.;
- Polley, E. C.; Shimelis, H.; Hart, S. N.; et al. Classification of variants of uncertain significance in
- 642 BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large
- 643 hereditary cancer multigene panel testing cohort. *Genet Med* **2020**, 22 (4), 701-708. DOI:
- 644 10.1038/s41436-019-0729-1 From NLM Medline.
- 645 (29) Easton, D. F.; Deffenbaugh, A. M.; Pruss, D.; Frye, C.; Wenstrup, R. J.; Allen-Brady, K.;
- Tavtigian, S. V.; Monteiro, A. N.; Iversen, E. S.; Couch, F. J.; et al. A systematic genetic
- 647 assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and
- 648 BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007, 81 (5), 873-883. DOI:
- 649 10.1086/521032 From NLM Medline.
- (30) Trapp, O.; Seeliger, K.; Puchta, H. Homologs of breast cancer genes in plants. *Front Plant*
- 651 *Sci* **2011**, *2*, 19. DOI: 10.3389/fpls.2011.00019 From NLM PubMed-not-MEDLINE.
- (31) Keeling, P. J.; Burki, F. Progress towards the Tree of Eukaryotes. Curr Biol 2019, 29 (16),
- 653 R808-R817. DOI: 10.1016/j.cub.2019.07.031 From NLM Medline.

- 654 (32) Al Jewari, C.; Baldauf, S. L. An excavate root for the eukaryote tree of life. Sci Adv 2023, 9
- 655 (17), eade4973. DOI: 10.1126/sciadv.ade4973 From NLM Medline.
- (33) Parsons, M. T.; de la Hoya, M.; Richardson, M. E.; Tudini, E.; Anderson, M.; Berkofsky-
- 657 Fessler, W.; Caputo, S. M.; Chan, R. C.; Cline, M. S.; Feng, B. J.; et al. Evidence-based
- 658 recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA
- 659 BRCA1 and BRCA2 Variant Curation Expert Panel. *Am J Hum Genet* **2024**, *111* (9), 2044-2058.
- 660 DOI: 10.1016/j.ajhg.2024.07.013 From NLM Medline.
- 661 (34) Grimm, D. G.; Azencott, C. A.; Aicheler, F.; Gieraths, U.; MacArthur, D. G.; Samocha, K. E.;
- 662 Cooper, D. N.; Stenson, P. D.; Daly, M. J.; Smoller, J. W.; et al. The evaluation of tools used to
- 663 predict the impact of missense variants is hindered by two types of circularity. *Hum Mutat* **2015**,
- 664 36 (5), 513-523. DOI: 10.1002/humu.22768 From NLM Medline.
- 665 (35) Starita, L. M.; Ahituv, N.; Dunham, M. J.; Kitzman, J. O.; Roth, F. P.; Seelig, G.; Shendure,
- 566 J.; Fowler, D. M. Variant Interpretation: Functional Assays to the Rescue. Am J Hum Genet

667 **2017**, *101* (3), 315-325. DOI: 10.1016/j.ajhg.2017.07.014 From NLM Medline.

- 668 (36) Fowler, D. M.; Rehm, H. L. Will variants of uncertain significance still exist in 2030? Am J
- 669 *Hum Genet* **2024**, *111* (1), 5-10. DOI: 10.1016/j.ajhg.2023.11.005 From NLM Medline.
- 670
- 671
- 672
- 673
- 674
- 675
- 676
- 677

678 FIGURE LEGENDS

679 **Figure 1**. Description of study flow

680 Functional assay results were combined with other data types (Exceptionally Conserved 681 Ancestral Residue (ECAR) or computational tool prediction) to evaluate the additivity 682 assumptions in the ACMG guidelines. Table 1: Tabulation of the number of functionally abnormal 683 variants (red line) that fall at ECAR positions. Table 2: A case control analysis and conversion to 684 ACMG points is then performed on these variants and results. Table 3: Functionally abnormal 685 variants that do not fall at ECAR positions are combined with predictions from six computational 686 tools, followed by a case control analysis and conversion to ACMG points. Table 4: Functionally 687 normal variants (blue line) from the assay are combined with computational tool predictions from 688 the same six tools, followed by a case control analysis and conversion to ACMG points.

689

690 **Figure 2**. Graphical Summary of Results

691 The matrix represents the main combinations of evidence evaluated in this study. The number in 692 the row or column headers represent the Bayesian point value assigned to each evidence type in 693 the ACMG guidelines. Each box has three lines: Expectation, Observed, and Percent of calls. 694 "Expectation" is the Bayesian points expected according to the ACMG guidelines. The 695 combination of ECAR, MAVE loss of function, and computational tool pathogenic was capped at 696 ≥+6 points. Otherwise expected points per category are additive as described in the ACMG 697 quidelines. The Observed line represents the Bayesian point value that was observed using the 698 MLE model in this study. The Percent all calls line represents the range, as a percent, of all 699 possible substitutions that were observed for a particular combination of evidence for the 700 computational tools evaluated. Blue filled boxes indicate that the combination of evidence met or 701 exceeded the ACMG guideline expectations in this study. Peach filled boxes indicate that the 702 combination of evidence departed from the expected additivity of the ACMG guideline in this 703 study. The bold black outline highlights that the assumption that MAVE LOF and computational

704	predictions of pathogenicity are additive is not met in this study; moreover, this combination had
705	a substantial number of observations. White filled boxes represent combinations of evidence
706	with little to no data. Dark grey filled boxes represent combinations of evidence with results that
707	may be beyond the dynamic range of the MLE model.
708	
709	
710	
711	
712	
713	
714	
715	
716	
717	
718	
719	
720	
721	
722	
723	
724	
725	
726	
727	
728	
729	

	Number of +4 Calls made by:								Other Models:	
Residue	Total Number of Possible snMS	LOF in SGE	AlphaMissense	BayesDel	MutPred2	REVEL	VEST4	BayesDel- VCEP ^a	A-GVGD	
C24	6	5	6	5	0	5	1	6	6	
C27	6	6	4	5	0	5	0	6	6	
C39	6	6	5	6	0	4	2	6	6	
H41	7	7	2	6	0	3	0	7	5	
C44	6	6	5	6	0	4	0	6	6	
C47	6	6	6	6	0	2	3	6	6	
C61	6	5	5	6	0	4	2	6	6	
C64	6	6	4	6	0	5	4	6	6	
T1685	5	5	0	0	0	0	0	3	1	
H1686	7	7	0	0	0	0	0	6	5	
T1700	6	5	0	0	0	0	0	6	3	
W1718	5	4	1	5	0	2	0	5	4	
R1753	5	5	0	0	0	0	0	5	4	
W1837	5	5	2	5	0	0	0	5	4	
Totals at ECAR positions	82	78 ^b	41	56	0	34	12	79	68	
Total ECAR snMS with LOF in SGE	78	78	39	53	0	32	11	75	65	
Totals with LOF via SGE assay	404	404	52	67	0	33	11	301	183	
Totals in RING/tBRCT domains	1,840	404	60	73	1	35	12	530	267	
Totals across BRCA1	11,009	NA	60	122	1	45	12	846	314	

Table 1. Predictions from SGE Functional Assay and Computational Tools at ECAR Positions.

ECAR = Exceptionally Conserved Ancestral Residue

snMS = Single Nucleotide Missense Substitution LOF = Loss of Function

SGE = Saturation Genome Editing

VCEP = Variant Curation Expert Panel

a. VCEP thresholds divide 'BayesDel no AF' scores into supporting benign, supporting pathogenic, and indeterminate scores. Scores ≥ 0.28 are supporting pathogenic.
 b. 4 variants at ECAR positions were not LOF. C24F, C61R, and W1718S had indeterminate results. T1700S was not interrogated in

the assay.

anomAD Adjusted 95% C.I. M.L.E Expected Possible Clinical Estimated Unique OR⁵ snMS^a Variant ACMG Obs. Obs. Proportion ACMG Point^d Pathogenic^c Point^e Obs. $1\overline{6.9} - 27.7$ Nonsense Substitutions 21.6 NA 213 1078 68 NA NA M2H Assay Categories 452 56 58 75 1.21 0.85 - 1.72 -3 -4 Functional 0.01 Indeterminate 17 14 NA NA 1 0 NA NA 0 235 22.6 24 13 12.9 - 39.51.00 100 4 Non-Functional – All 4 14 220 24.8 Non-functional – ECAR 50 11 13.5 - 45.61.00 ≥6 6 Non-functional – Other 50 15 2 21.6 2.23 - 43.90.74 10 4 4 SGE Assay Categories 1.185 239 0.64 - 1.00121 0.80 0.00 -4 Functional 154 -4 Indeterminate 28 36 24 2.51 1.48 - 4.25148 0 0 0.16 413 77 413 37 16.3 11.6 – 27.7 4 4 Non-Functional – All 0.88

26.2^h

12.0^h

1.32

NA

1.48

0.46

14.3 – 48.1

7.9 – 18.1

0.76 - 2.29

0.87 - 25.2

0.50 - 4.24

NA

1.00

0.71

0.05

NA

0.06

0.00

6

4

-4

0

4

2

≥6

4

-1

0

-4

NA

Table 2. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Functional Assay Analytical Subsets and Non-functional Substitutions Falling at ECAR Positions.

11

26

27

15

1

4

ACMG = American College of Medical Genetics and Genomics

89

324

152

15

16

22^g

19

58

14

2

2

5

231

182

26

0

1

1

ECAR = Exceptionally Conserved Ancestral Residue

snMS = Single Nucleotide Missense Substitution

Obs. = Observations

OR = Odds Ratio

C.I. = Confidence Interval

HDR Assay Categories

Non-Functional – All

Functional

Indeterminate

A Priori Damaging^f

M.L.E = Maximum Likelihood Estimate

Non-functional – ECAR

Non-functional – Other

NA = Not Applicable

M2H = Mammilian-2-Hybrid

SGE = Saturation Genome Editing

ECAR = Exceptionally Conserved Ancestral Residue

HDR = Homology Directed Repair

a. Restricted to those snMS interrogated in the assay indicated.

b. Adjusted for race/ethnicity.

c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.

d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.

e. The expected points from combining evidence categories according to ACMG guidelines.

f. This subset interrogates the substitutions to Proline and other non-conservative amino acid substitutions that fell at the a,d positions of the alpha helix in the coiled-coil domain (M1400, Q1401, H1402, L1404, L1407, Q1408, Q1409, M1411, A1412, L1414, A1416, L1418), regardless of whether they were interrogated in the assay. Only Q1401P was included in the assay and had no clinical or gnomAD observations in our dataset.

g. This is the total number of possible substitutions listed in footnote e. irrespective of inclusion in the HDR assay of the coiled coil domain.

h. Indicates that these ORs are statistically significant from one another.

Computational	Possible	Unique	Clinical	gnomAD	Adjusted	95% C.I.	M.L.E	Estimated	Expected
Tool Prediction	snMSª	Variants	Obs.	Obs.	OR⁵		Proportion	ACMG	ACMG
		Obs.					Pathogenic ^c	Point ^d	Point ^e
A-GVGD									
Pathogenic	120	23	95	11	14.9	7.97 – 28.0	0.79	4	5
Indeterminate	120	20	71	11	10.9	5.72 – 20.6	0.68	3	4
Benign	91	15	16	4	6.80	2.24 – 20.6	0.49	2	3
AlphaMissense									
Pathogenic	232	43	171	19	15.4	9.56 - 24.8	0.81	4	5
Indeterminate	80	14	9	7	2.03	0.86 - 10.4	0.12	1	4
Benign	13	1	2	0	NA	NA	NA	NA	3
BayesDel									
Pathogenic	284	52	175	25	11.9	7.80 – 18.2	0.71	4	5
Indeterminate	46	6	7	1	13.5	1.64 – 110.8	0.71	4	4
Benign	0	0	0	0	NA	NA	NA	NA	3
BayesDel -									
VCEP									
Pathogenic	231	47	170	23	12.6	8.14 – 19.6	0.73	4	5
Indeterminate	45	5	5	2	3.62	0.68 – 19.2	0.32	1	4
Benign	55	6	7	1	13.5	1.64 – 110.8	0.71	4	3
MutPred2									
Pathogenic	142	30	115	15	13.4	7.82 – 23.7	0.75	4	5
Indeterminate	159	25	65	10	10.6	5.40 - 20.7	0.68	3	4
Benign	29	3	2	1	3.52	0.31 – 40.4	0.24	1	3
REVEL									
Pathogenic	285	52	175	25	11.9	7.80 – 18.3	0.71	4	5
Indeterminate	46	6	7	1	13.5	1.64 – 110.8	0.71	4	4
Benign	0	0	0	0	NA	NA	NA	NA	3
VEST4									
Pathogenic	213	43	167	21	13.5	8.54 – 21.3	0.76	4	5
Indeterminate	108	15	15	5	5.49	1.97 – 15.3	0.38	2	4
Benign	10	0	0	0	NA	NA	NA	NA	3

 Table 3. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Non-functional, Non-ECAR Assay Results

 Combined with Computational Predictions.

ACMG = American College of Medical Genetics and Genomics

ECAR = Exceptionally Conserved Ancestral Residue

snMS = Single Nucleotide Missense Substitution

Obs. = Observations

OR = Odds Ratio

C.I. = Confidence Interval

M.L.E = Maximum Likelihood Estimate

NA = Not Applicable

VCEP = Variant Curation Expert Panel

a. Restricted to those snMS interrogated in the assay indicated.

b. Adjusted for race/ethnicity.

c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.

d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.

e. The expected points from combining evidence categories according to ACMG guidelines.

Computational	Possible	Unique	Clinical	gnomAD	Adjusted	95% C.I.	M.L.E	Estimated	Expected
Tool Prediction	snMSª	Variant Obs.	Obs.	Obs.	OR⁵		Proportion Pathogenic ^c	ACMG Point ^d	ACMG Point ^e
A-GVGD									
Pathogenic	61	9	11	8	2.53 ^f	1.00 - 6.38	0.32	1	-3
Indeterminate	212	25	40	43	1.45	0.93 – 2.26	0.10	0	-4
Benign	912	120	70	188	0.58 ^f	0.44 – 0.77	0.00	-5	-5
AlphaMissense									
Pathogenic	122	19	19	17	1.70 ^f	0.87 – 3.32	0.20	1	-3
Indeterminate	586	78	78	115	1.07	0.80 – 1.44	0.00	-4	-4
Benign	477	57	24	107	0.36 ^f	0.23 - 0.56	0.00	-5	-5
BayesDel									
Pathogenic	379	54	65	77	1.36	0.97 – 1.90	0.06	0	-3
Indeterminate	769	95	54	155	0.54	0.36 – 0.74	0.00	-4	-4
Benign	37	5	2	7	0.52	0.11 – 2.55	0.00	-5	-5
BayesDel - VCEP									
Pathogenic	152	20	21	28	1.21 ^f	0.68 – 2.15	0.00	-4	-3
Indeterminate	181	29	35	45	1.20	0.76 – 0.83	0.02	-3	-4
Benign	852	105	65	166	0.62 ^f	0.46 - 0.83	0.00	-5	-5
MutPred2									
Pathogenic	86	6	4	7	1.10	0.32 – 3.81	0.00	-4	-3
Indeterminate	399	57	62	79	1.14	0.81 – 1.61	0.02	-2	-4
Benign	697	91	55	153	0.60	0.44 – 0.82	0.00	-5	-5
REVEL									
Pathogenic	413	52	56	85	1.08	0.77 – 1.52	0.00	-4	-3
Indeterminate	769	102	65	154	0.49	0.36 - 0.68	0.00	-4	-4
Benign	3	0	0	0	NA	NA	NA	NA	-5
VEST4									
Pathogenic	116	14	19	15	2.56 ^f	1.29 – 5.07	0.27	1	-3
Indeterminate	763	100	84	139	0.88	0.67 – 1.16	0.00	-4	-4
Benign	306	40	18	85	0.37 ^f	0.22 - 0.62	0.00	-5	-5

 Table 4. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Functionally Normal Assay Results Combined

 with Computational Predictions.

ACMG = American College of Medical Genetics and Genomics

snMS = Single Nucleotide Missense Substitution

Obs. = Observations

OR = Odds Ratio

C.I. = Confidence Interval

M.L.E = Maximum Likelihood Estimate

NA = Not Applicable

VCEP = Variant Curation Expert Panel

a. Restricted to those snMS interrogated in the assay indicated.

b. Adjusted for race/ethnicity.

c. The OR threshold used for this calculation is that of moderate risk variants (OR = 2) adjusted for observational inflation in our data to OR = 4.4.

d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.

e. The expected points from combining evidence categories according to ACMG guidelines.

f. Indicates that these ORs are statistically significant from one another. Comparison is made between the predicted benign and predicted pathogenic categories for a given computational tool.




Figure 2			Substitution	at ECAR (+2)	Substitution at non-ECAR (+0)			
			MAVE LOF (+4)	MAVE Functional (-4)	MAVE LOF (+4)	MAVE Functional (-4)		
		(+1)	$\frac{\text{Expectation:}}{\geq +6 \text{ ACMG Points}}$	Expectation: -1 ACMG Points	Expectation: +5 ACMG Points	Expectation: -3 ACMG Points		
	Prediction	nogenic	nogenic	<u>Observed:</u> ≥+6	<u>Observed:</u> NA	<u>Observed:</u> +4	<u>Observed:</u> -4 to +1	
		Pathe	Percent of calls: (2.67% - 4.25%)	Percent of calls: (0.00%)	<u>Percent of calls:</u> (6.42% - 15.24%)	Percent of calls: (3.32% - 22.65%)		
	Computational	1)	Expectation: +5 ACMG Points	Expectation: -3 ACMG Points	Expectation: +3 ACMG Points	Expectation: -5 ACMG Points		
	Comp	enign (-	<u>Observed:</u> NA	<u>Observed:</u> NA	<u>Observed:</u> +1 to +4	<u>Observed:</u> ≤-5		
		ā	Percent of calls: (0.00% - 0.11%)	Percent of calls: (0.00%)	Percent of calls: (0.00% - 4.90%)	Percent of calls: (0.16% - 54.98%)		

= Meets or exceeds expectations

= Departs from expected additivity



= Limited sensitivity between invdividual points